Drug Guidance for Subsidy 17/02/2025 Deucravacitinib for moderate-to-severe chronic plaque psoriasis NRThe Ministry of Health’s Drug Advisory Committee has not recommended deucravacitinib for inc... See all × 17/02/2025 Deucravacitinib for moderate-to-severe chronic plaque psoriasis NRThe Ministry of Health’s Drug Advisory Committee has not recommended deucravacitinib for inclusion on the MOH List of Subsidised Drugs for treating moderate-to-severe chronic plaque psoriasis. The decision was based on the unfavourable clinical and cost effectiveness of deucravacitinib compared with adalimumab, and the unacceptable price-volume agreement proposed by the company.